1. Kim JH, Choi W, Kim KC, et al. The current status of intervention for intermediate coronary stenosis in the Korean percutaneous coronary intervention (K-PCI) registry. Korean Circ J. 2019; 49:1022–1032. PMID:
31190480.
Article
2. Moses JW, Leon MB, Popma JJ, et al. Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med. 2003; 349:1315–1323. PMID:
14523139.
Article
3. El-Hayek G, Bangalore S, Casso Dominguez A, et al. Meta-analysis of randomized clinical trials comparing biodegradable polymer drug-eluting stent to second-generation durable polymer drug-eluting stents. JACC Cardiovasc Interv. 2017; 10:462–473. PMID:
28279314.
Article
4. Spaulding C, Daemen J, Boersma E, Cutlip DE, Serruys PW. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med. 2007; 356:989–997. PMID:
17296825.
Article
5. Stefanini GG, Holmes DR Jr. Drug-eluting coronary-artery stents. N Engl J Med. 2013; 368:254–265. PMID:
23323902.
Article
6. Heller R, Unbehaun A, Schellenberg B, Mayer B, Werner-Felmayer G, Werner ER. L-ascorbic acid potentiates endothelial nitric oxide synthesis via a chemical stabilization of tetrahydrobiopterin. J Biol Chem. 2001; 276:40–47. PMID:
11022034.
Article
7. Gordon PC, Gibson CM, Cohen DJ, Carrozza JP, Kuntz RE, Baim DS. Mechanisms of restenosis and redilation within coronary stents--quantitative angiographic assessment. J Am Coll Cardiol. 1993; 21:1166–1174. PMID:
8459072.
Article
8. Lim YH, Youn JH, Hong SJ, et al. A first-in-man clinical evaluation of sirolimus and ascorbic acid-eluting stent systems; a multicenter, subject-blinded, randomized study. Korean Circ J. 2021; 51:1001–1014.
Article
9. Wenaweser P, Daemen J, Zwahlen M, et al. Incidence and correlates of drug-eluting stent thrombosis in routine clinical practice. 4-year results from a large 2-institutional cohort study. J Am Coll Cardiol. 2008; 52:1134–1140. PMID:
18804739.